Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Inflarx N.V.
Industry Sector: HealthTechnology
CEO: Niels Christoph Riedemann, MD, PhD
Number Of Employees: 74
Enterprise Value: $91,651,865
PE Ratio: -0.89
Exchange/Ticker 1: NASDAQ:IFRX
Exchange/Ticker 2: N/A
Latest Market Cap: $62,830,100
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New I&I indications take center stage
Inflammation and immunology readouts to define new priority indications, modality opportunities in immune reset
BioCentury | Nov 16, 2024
Data Byte
EMA’s CHMP finds path to Leqembi nod, backs three other new drugs
Eleven label expansions also among committee’s November recommendations
BioCentury | Feb 24, 2024
Management Tracks
Petroutsas to lead U.S. commercial operations at Astellas
Plus: Evan Ballantyne named CFO at Hansa and updates from BostonGene and InflaRx
BioCentury | Aug 30, 2023
Regulation
Aug. 30 Quick Takes: With Embark acquisition, Novo gains another obesity asset
Plus: Epigenome editing company Epigenic raises $32M series A and updates from Outlook, InflaRx, Zealand and FDA
BioCentury | Jul 7, 2023
Management Tracks
Zai promotes Chen to CFO
Plus: Chiesi elevates next generation, Lang now Lyell’s CBO and updates from OrbiMed, Gimv, Nkarta, InflaRx, Akamis and more
BioCentury | Apr 4, 2023
Deals
April 4 Quick Takes: Scorpion, Pierre Fabre enter deal for pair of EGFRs
Plus: EUA for InflaRx’s antibody for COVID-19 and updates from Adcendo, Mercy, Mosaic, Freeline and Gossamer
BioCentury | Sep 29, 2022
Deals
Sept. 29 Quick Takes: New life for Idera via Aceragen acquisition
Plus Biohaven’s verdiperstat misses again and updates from Meliora, Sarepta and more
BioCentury | Sep 16, 2022
Product Development
When site-specific trial stratification is a bad idea
InflaRx: a case study of wrong statistical methodology leading to an erroneous outcome
BioCentury | Apr 1, 2022
Finance
March 31 Quick Takes: V-Bio, HealthQuad close venture funds
Plus CDMO Abzena raises $65M, Clovis meets in ovarian cancer, InflaRx misses in COVID, FDA updates COVID EUA guidance and more
BioCentury | Nov 17, 2021
Product Development
Nov. 16 Quick Takes: Pfizer requests EUA, enters patent pool
Plus InflaRx, Vumerity, Twist, Synthace, Molecular Partners, Merck KGaA, Sotio-LegoChem and Kezar
Items per page:
1 - 10 of 24